Generic placeholder image

Recent Patents on Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 1872-213X
ISSN (Online): 2212-2710

Bench to Bedside of CTLA-4: A Novel Immuno-Therapeutic Agent for Inflammatory Disorders

Author(s): Priya Sakthivel

Volume 3 , Issue 2 , 2009

Page: [84 - 95] Pages: 12

DOI: 10.2174/187221309788489805

Price: $65

Abstract

Co-stimulatory molecules are antigen-independent generators of secondary signals which aid in maintaining the homeostasis of the immune system. CTLA-4 is one among extensively studied co-stimulatory molecules which downregulate immune response. The attributes of immunosuppressive qualities and capacity to induce tolerance have made its recognition as a potential immuno-therapeutic agent for autoimmune mediated inflammatory disorders. In 2007, European Medical Drug Agency (EMEA) has approved administration of CTLA-4Ig (commercial name: Orencia® ; generic name: Abatacept), as a mean for co-stimulation blockade, for treating patients with rheumatoid arthritis. This review is focused on working mechanism of CTLA-4 from its recognition (bench) to its usage as a potential therapeutic agent (bedside) for several inflammatory diseases. The efficacious aspects of chimeric CTLA-4 in phase I, II and III clinical trials for rheumatoid arthritis, psoriasis, multiple sclerosis are concisely described. This article highlights recent patents and the future usage of co-stimulatory molecules as a therapeutic agent providing a promising immuno-modulatory approach in regulating inflammation.

Keywords: CTLA-4, co-stimulatory molecules, abatacept, Inflammation, rheumatoid arthritis, multiple sclerosis, psoriasis vulgaris


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy